In conclusion, the current study demonstrates that SphK2 is an essential lipid regulator in NAFLD-associated HCC, providing experimental evidence to support clinical trials of SphK2 inhibitors as systemic therapies against HCC. The gene discussed is SPHK2; the disease is metabolic dysfunction-associated steatotic liver disease.